Literature DB >> 299894

Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues.

J A Straw, D C Talbot, G A Taylor, K R Harrap.   

Abstract

Thymidine, in the absence of hypoxanthine, failed to protect normal mice from the acute toxicity of methotrexate, though tumor-bearing animals could be protected with thymidine alone, probably as a result of the availability of DNA degradation products released from drug-sensitive tumor cells. Although metrotrexate induced an early purine deficiency in gut cells, this effect was not detected in bone marrow. Later, purine deficiency became apparent in the gut and bone marrow of methotrexate-treated animals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 299894     DOI: 10.1093/jnci/58.1.91

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

1.  Clinical use of thymidine as a rescue agent from methotrexate toxicity.

Authors:  J L Grem; S A King; J M Sorensen; M C Christian
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

2.  Transition from laboratory to clinic in cancer treatment. Abstracts of symposium papers.

Authors: 
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

3.  Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

Authors:  B J Braakhuis; E J Schoevers; E C Heinerman; G Sneeuwloper; G B Snow
Journal:  Br J Cancer       Date:  1983-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.